
BEAT Valuation
Heartbeam Inc
- Overview
- Forecast
- Valuation
- Earnings
BEAT Relative Valuation
BEAT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BEAT is overvalued; if below, it's undervalued.
Historical Valuation
Heartbeam Inc (BEAT) is now in the Fair zone, suggesting that its current forward PS ratio of 23.75 is considered Fairly compared with the five-year average of -2.80. The fair price of Heartbeam Inc (BEAT) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price:1.35
Fair
-2.18
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Heartbeam Inc. (BEAT) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.00
EV/EBIT
Heartbeam Inc. (BEAT) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is -1.95. The thresholds are as follows: Strongly Undervalued below -5.17, Undervalued between -5.17 and -3.56, Fairly Valued between -0.34 and -3.56, Overvalued between -0.34 and 1.27, and Strongly Overvalued above 1.27. The current Forward EV/EBIT of 0.00 falls within the Overvalued range.
23.75
PS
Heartbeam Inc. (BEAT) has a current PS of 23.75. The 5-year average PS is 89.88. The thresholds are as follows: Strongly Undervalued below -503.61, Undervalued between -503.61 and -206.86, Fairly Valued between 386.62 and -206.86, Overvalued between 386.62 and 683.36, and Strongly Overvalued above 683.36. The current Forward PS of 23.75 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Heartbeam Inc. (BEAT) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.09. The thresholds are as follows: Strongly Undervalued below -5.89, Undervalued between -5.89 and -3.99, Fairly Valued between -0.19 and -3.99, Overvalued between -0.19 and 1.71, and Strongly Overvalued above 1.71. The current Forward P/OCF of 0.00 falls within the Overvalued range.
0.00
P/FCF
Heartbeam Inc. (BEAT) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.92. The thresholds are as follows: Strongly Undervalued below -8.76, Undervalued between -8.76 and -5.34, Fairly Valued between 1.50 and -5.34, Overvalued between 1.50 and 4.92, and Strongly Overvalued above 4.92. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Heartbeam Inc (BEAT) has a current Price-to-Book (P/B) ratio of 10.98. Compared to its 3-year average P/B ratio of 5.47 , the current P/B ratio is approximately 100.64% higher. Relative to its 5-year average P/B ratio of 4.41, the current P/B ratio is about 148.90% higher. Heartbeam Inc (BEAT) has a Forward Free Cash Flow (FCF) yield of approximately -33.65%. Compared to its 3-year average FCF yield of -27.46%, the current FCF yield is approximately 22.51% lower. Relative to its 5-year average FCF yield of -29.02% , the current FCF yield is about 15.95% lower.
10.98
P/B
Median3y
5.47
Median5y
4.41
-33.65
FCF Yield
Median3y
-27.46
Median5y
-29.02
Competitors Valuation Multiple
The average P/S ratio for BEAT's competitors is 5.54, providing a benchmark for relative valuation. Heartbeam Inc Corp (BEAT) exhibits a P/S ratio of 23.75, which is 328.71% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BEAT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BEAT in the past 1 year is driven by Unknown.
People Also Watch

IMMX
Immix Biopharma Inc
2.220
USD
-3.06%

CNVS
Cineverse Corp
4.890
USD
-5.60%

BOLD
Boundless Bio Inc
1.120
USD
-1.75%

SST
System1 Inc
7.120
USD
-3.91%

BAFN
Bayfirst Financial Corp
9.020
USD
-4.45%

FURY
Fury Gold Mines Ltd
0.511
USD
+0.39%

CTSO
Cytosorbents Corp
0.943
USD
+0.86%

APYX
Apyx Medical Corp
1.990
USD
-1.49%

AREC
American Resources Corp
2.060
USD
-1.44%
FAQ

Is Heartbeam Inc (BEAT) currently overvalued or undervalued?
Heartbeam Inc (BEAT) is now in the Fair zone, suggesting that its current forward PS ratio of 23.75 is considered Fairly compared with the five-year average of -2.80. The fair price of Heartbeam Inc (BEAT) is between to according to relative valuation methord.

What is Heartbeam Inc (BEAT) fair value?

How does BEAT's valuation metrics compare to the industry average?

What is the current P/B ratio for Heartbeam Inc (BEAT) as of Sep 01 2025?

What is the current FCF Yield for Heartbeam Inc (BEAT) as of Sep 01 2025?

What is the current Forward P/E ratio for Heartbeam Inc (BEAT) as of Sep 01 2025?
